A5002622033- Radiomics and Machine Learning in Medical Imaging
- Gene expression and cancer classification
- Traditional Chinese Medicine Studies
- Cancer Genomics and Diagnostics
- Molecular Biology Techniques and Applications
- Genetics, Bioinformatics, and Biomedical Research
- BRCA gene mutations in cancer
- Cervical Cancer and HPV Research
- Breast Cancer Treatment Studies
- Biomedical Text Mining and Ontologies
- Multiple and Secondary Primary Cancers
- Amoebic Infections and Treatments
- Neuroblastoma Research and Treatments
- Genetic factors in colorectal cancer
- Hematological disorders and diagnostics
- Artificial Intelligence in Healthcare
- Nutrition, Genetics, and Disease
- Web and Library Services
- Economic and Financial Impacts of Cancer
- Radio, Podcasts, and Digital Media
- Machine Learning in Bioinformatics
- Biological Research and Disease Studies
- Social Media in Health Education
- Lung Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
Camden and Campbelltown Hospitals
2021
Western Sydney University
2021
Changhai Hospital
2019
Fudan University
2019
Second Military Medical University
2019
A 32-month-old female child with a history of stage IV favorable biology neuroblastoma 123-I MIBG (metaiodobenzylguanidine scan) avid adrenal mass, retroperitoneal nodal extension and bony metastasis, was in complete remission after intense multimodal therapy. Seventeen months diagnosis surveillance scan showed abnormal tracer uptake the midzone right thorax. Chest x-ray CT confirmed upper lobe consolidation corresponding to uptake. antibiotics resolution abnormality. 3 later no...
Routine health checkup is an essential strategy for monitoring population and maintaining healthy workforces. However, there was a lack of cancer screening tests among routine checkups due to high costs unreliable methods.We conducted two-stage study evaluate the value blood test, Cancer Differentiation Analysis (CDATM), which developed differentiate samples individuals from those patients through measuring analyzing multiple biophysical properties.The first stage cross-sectional included...
e22509 Background: The current cancer screening approach is relatively expensive and unable to cover all general population. Certain amount of information collected possibly “overkill” at the expense costs technology complexity as statistically only 2-3 individuals in very one thousand have cancer. We propose a novel multi-cancer for population which based on initial objectives, new occurrence mechanism, cost model. Since step following diagnosis significant tests will be carried out, we...
10539 Background: Multi-cancer screening has become a major approach for early stage cancer and prevention. However, there been very few reported multi-year, multi-cancer follow-up studies to validate the effectiveness of screening. We report number significant, findings from what we believe first large scale, study. Methods: In this study, differentiation analysis (CDA) technology, bio-physics based detection platform, used screen over 200,000 individuals in general population. Based on CDA...
13 Background: A newly developed in-vitro diagnostic technology named Cancer Differentiation Analysis Technology (CDA) was investigated for breast cancer screening. The CDA is a blood-sample based, multi-level, multi-parameter method which detects signals from both proteins and cells, in multiple aspects parameters of information were collected to improve accuracy. Methods: Blood samples group (n = 222), control subjects 204) EDTA tubes. values measured using medical device. results shown...
e15059 Background: For esophageal cancer, no viable non-invasive detection technologies are available today. In this investigation, a newly developed IVD cancer diagnostic technology named Cancer Differentiation Analysis Technology (CDA) was investigated for detection. CDA technology, multi-level and multi-parameter information is collected using medical device fabricated by Anpac Bio-Medical Science Co., Ltd. which measures relating to both protein fragments cellular signals in blood...
e22171 Background: A newly developed diagnostic technology named Cancer Differentiation Analysis Technology (CDA) was investigated for hepatocellular carcinoma (HCC) screening. The CDA is a blood-sample based, multi-level, multi-parameter method which detects signals from both proteins and cells, in multiple aspects of information collected to improve accuracy. Methods: Blood samples patients with HCC (n = 511), cirrhosis 71) other benign liver diseases (BLD) 46), as well control subjects...
e12578 Background: Despite efforts in recent years, major progress cancer diagnosis remains to be elusive. Existing issues include inability detect early, relatively low sensitivity and specificity, side effects (for some imaging based technologies), high costs. In this work, an initial evaluation was carried out on of two digestive sites, hepatocellular carcinoma (HCC) colorectal cancer, using a method named Cancer Differentiation Analysis technology (CDA) which measures both protein...
e12587 Background: Non-small cell lung cancer (NSCLC) is one of the most common cancers in world. The high mortality rate partly due to that current image-based technologies are not sensitive enough screen early incidences. A new diagnostics method, named Cancer Differentiation Analysis Technology (CDA hereafter), was developed for diagnosis cancer. In CDA technology, multi-level and multi-parameter data information including protein fragments cellular collected while existing single...
e23176 Background: The diagnostic accuracy of Cancer Differentiation Analysis (CDA) Technology has been evaluated and verified in previous studies (Abstract No. e12578, e22171, e12587, e15059). aim this study is to investigate the potential capability CDA technology for breast cancer prognosis. Methods: Blood samples (n = 45) collected from 3 cases during course post-operative treatment (POT) were tested by technology. Information includes clinical stage, histology, protocols (TP) so on. Due...
564 Background: Currently endoscopy examination takes an important role in the diagnosis of colorectal cancer, and there are no other clinically viable non-invasive diagnostic methods. In this investigation, a newly developed, novel IVD cancer technology named Cancer Differentiation Analysis (CDA) Technology was investigated for diagnosis. CDA is new using multi-level multi-parameter information which measures relating to both protein fragments cellular signals blood samples one single test....
42 Background: For esophageal cancer, no viable non-invasive detection technologies are available today. In earlier investigations, Cancer Differentiation Analysis (CDA) Technology which measures information relating to both protein fragments and cellular signals in blood samples a single test has showed significant advantage cancer diagnosis. Methods: Blood from 105 individuals EDTA tubes were collected Shanghai Changhai Hospital, China, between July December 2014, CDA endoscopy tests...
e23131 Background: Cancer Differentiation Analysis liquid biopsy (CDA) has been investigated as a viable clinical utility in NSCLC diagnosis, well new candidate for part of an overall post-CT scan diagnostic and treatment decision tool kit. It also evaluated combined with imaging technologies. Methods: This was retrospective investigation which 160 individuals were recruited at Changhai Hospital Shanghai from July to Dec. 2014. CDA CT tests performed on all samples before final confirmation...
Abstract Background: An emerging novel liquid biopsy technology called Cancer Differentiation Analysis (CDA) has been evaluated as a viable early stage breast cancer screening tool. CDA is blood-sample based, multi-level, multi-parameter diagnostic method which detects signals from both protein, cellular, and to some extent, molecular levels, in multiple aspects of information can be collected improve accuracy, even for cancer. Improving capability screen an important on-going research...
e20673 Background: Early stage cancer detection remains to be elusive despite of many years efforts. In this work, a bio-physical based marker (named Cancer Differentiation Analysis (CDA)) with multi-level and multi-parameter expression features has been developed which shown number clear advantages over the traditional approaches such as bio-chemistry marker, circulating tumor cell (CTC) circuiting DNA (ct-DNA). I non-small lung (NSCLC), sensitivity specificity reached record high 85.2%...
2040 Background: While the current cancer screening methods mostly failed to detect cerebral cancer, a novel, promising technology named differentiation analysis (CDA) has been developed measure novel bio-physical properties obtain valuable multi-level and multi-parameter information including protein, cellular molecular level information. Initial results showed that CDA is capable of detecting with high degree sensitivity specificity. Methods: In this study, samples from 78 patients 321...